Uppsala, Sweden, February 13, 2018 / B3C newswire / -- Biotage (STO: BIOT), a leading global supplier of solutions and technology for analytical, medicinal and peptide chemistry, is pleased to announce the launch of ISOLUTE® HYDRO DME+ fixed well plates and columns, for the efficient removal of matrix components from urine, using a simple pass through workflow.
The novel (patent pending) dual mode extraction (DME) methodology has been developed by Biotage to provide more effective removal of matrix components such as salts, creatinine, urea, pigments and residual hydrolysis enzymes from urine using a combination of liquid partitioning and scavenging modes. Compared to the dilute and shoot approach, analyte sensitivity is increased, and instrument sensitivity is maintained over multiple injections, improving assay robustness and reducing costly downtime. The inclusion of Biotage® HYDRO frit technology means that urine samples can be hydrolyzed in-situ in the well or column, eliminating the need for a post hydrolysis sample transfer step.
ISOLUTE® HYDRO DME+ products can be processed using 96-well compatible positive pressure manifolds (e.g. Biotage® PRESSURE+ 96/48), vacuum manifolds (e.g. VacMaster™-96/-10-20) and automated sample extraction systems (e.g. Biotage® Extrahera). Raw urine samples of up to 200 µL can be cleaned up using the 400 mg 96-well plate and column formats.
“ISOLUTE® HYDRO DME+ is an ideal urine clean-up product, for the simple, rapid and cost effective purification of urine matrices prior to LC-MS/MS analysis. Extracts are cleaner, meaning analytical column lifetime is extended, MS downtime is reduced and sensitivity maintained for longer” said Dr. Claire Desbrow, Global Product Manager, Analytical Chemistry, Biotage.
For further information visit www.biotage.com or call: in Europe +46 18 56 57 10, in North America toll free 1 800 446 4752, in Japan +81 3 5627 3123, other areas please call +46 18 56 57 10.
Biotage offers solutions, knowledge and experience in the areas of analytical and medicinal chemistry. Customers include the world’s top pharmaceutical and biotechnology companies, as well as leading academic institutes. The company is headquartered in Uppsala, Sweden, with offices in South Korea, China, Japan, the United Kingdom, the United States and a worldwide network of distributors. Biotage has 308 employees, with sales of 667 MSEK in 2016. Biotage is listed on the NASDAQ OMX Nordic Stock Exchange.
Marketing Communications Manager
Biotage GB Ltd.
Distribution Way, Dyffryn Business Park
Ystrad Mynach, Hengoed
Wales CF82 7TS United Kingdom
phone: +44 (0)1443 811 849
mobile: +44 (0) 7875 484778